Human programmed cell death protein (PD-1) variants
By introducing specific amino acid mutations at specific sites in the loop 1 region of the PD-1 protein, a PD-1 protein variant with enhanced binding affinity was developed, solving the problem of insufficient binding affinity in existing technologies and enhancing tumor suppression effects.
CN122249457APending Publication Date: 2026-06-19JIECO BIOPHARMACEUTICALS
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- JIECO BIOPHARMACEUTICALS
- Filing Date
- 2024-07-29
- Publication Date
- 2026-06-19
AI Technical Summary
Technical Problem
Existing PD-1 protein variants have low binding affinity to PDL-1 and PDL-2, limiting their effectiveness in immunotherapy.
Method used
By introducing specific amino acid mutations into the loop 1 region of the PD-1 protein, a PD-1 protein variant with improved binding affinity was developed. The increased binding affinity was further enhanced by fusion with the Fc amino acid sequence to improve bioavailability.
Benefits of technology
It improved the binding affinity of PD-1 protein variants to PDL-1 and PDL-2, enhancing their efficacy in immunotherapy, particularly their in vivo activity in tumor suppression.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122249457A_ABST
Abstract
This disclosure provides amino acid sequence variants of programmed cell death protein 1 (PD-1) that can bind to one or both of its ligands, PDL-1 or PDL-2. This disclosure relates to ligand-binding fragments, conjugates, and related compositions and formulations of PD-1 variant sequences. This disclosure also relates to methods of treating subjects with checkpoint pathway-related diseases, conditions, and symptoms and / or immunocompromised individuals using said sequences, such as PD-1 variants and their ligand-binding fragments, including proliferative disorders such as cancer, and diseases, conditions, and symptoms associated with immunodeficiency or immune dysfunction.
Need to check novelty before this filing date? Find Prior Art